Items where authors include "Blanchard, F."

Article

Kemppainen, J., Scales, B., Razban Haghighi, K. et al. (20 more authors) (2022) Binocular mirror–symmetric microsaccadic sampling enables Drosophila hyperacute 3D vision. Proceedings of the National Academy of Sciences, 119 (12). e2109717119. ISSN 0027-8424

Kemppainen, J., Scales, B., Razban Haghighi, K. et al. (20 more authors) (2021) Binocular mirror-symmetric microsaccadic sampling enables Drosophila hyperacute 3D-vision. bioRxiv. (Submitted)

Li, X., Abou Tayoun, A., Song, Z. et al. (12 more authors) (2019) Ca2+-activated K+ channels reduce network excitability, improving adaptability and energetics for transmitting and perceiving sensory information. Journal of Neuroscience, 39 (36). pp. 7132-7154. ISSN 0270-6474

Juusola, M.I. orcid.org/0000-0002-4428-5330, Dau, A., Song, Z. et al. (8 more authors) (2017) Microsaccadic sampling of moving image information provides Drosophila hyperacute vision. eLife, 6. e26117. ISSN 2050-084X

Guihard, P., Boutet, M-A., Royer, BB-L. et al. (8 more authors) (2015) Oncostatin M, an Inflammatory Cytokine Produced by Macrophages, Supports Intramembranous Bone Healing in a Mouse Model of Tibia Injury. American Journal of Pathology, 185 (3). pp. 765-775. ISSN 0002-9440

Gobin, B., Baud'Huin, M., Lamoureux, F. et al. (8 more authors) (2015) BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. International Journal of Cancer, 136 (4). pp. 784-796. ISSN 0020-7136

Darrieutort-Laffite, C., Boutet, M-A., Chatelais, M. et al. (4 more authors) (2014) IL-1 beta and TNF alpha Promote Monocyte Viability through the Induction of GM-CSF Expression by Rheumatoid Arthritis Synovial Fibroblasts. Mediators of Inflammation, 2014. 241840. ISSN 0962-9351

Gobin, B., Moriceau, G., Ory, B. et al. (5 more authors) (2014) Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models. PLoS ONE, 9 (3). e90795. ISSN 1932-6203

Monderer, D., Luseau, A., Bellec, A. et al. (14 more authors) (2013) New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Laboratory Investigation, 93 (10). pp. 1100-1114. ISSN 0023-6837

David, E., Tirode, F., Baud'huin, M. et al. (7 more authors) (2012) Oncostatin M Is a Growth Factor for Ewing Sarcoma. The American Journal of Pathology, 181 (5). pp. 1782-1795. ISSN 0002-9440

Guihard, P., Danger, Y., Brounais, B. et al. (9 more authors) (2012) Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling. Stem Cells, 30 (4). pp. 762-772. ISSN 1066-5099

Chemel, M., Le Goff, B., Brion, R. et al. (10 more authors) (2012) Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Annals of the Rheumatic Diseases (ARD), 71 (1). pp. 150-154. ISSN 0003-4967

David, E., Guihard, P., Brounais, B. et al. (10 more authors) (2011) Direct anti-cancer effect of oncostatin M on chondrosarcoma. International Journal of Cancer, 128 (8). pp. 1822-1835. ISSN 0020-7136

David, E., Blanchard, F., Heymann, M.F. et al. (4 more authors) (2011) The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets. Sarcoma, 2011. 932451. ISSN 1357-714X

Moriceau, G., Ory, B., Mitrofan, L. et al. (11 more authors) (2010) Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process. Cancer Research, 70 (24). pp. 10329-10339. ISSN 0008-5472

Le Goff, B., Blanchard, F., Berthelot, J-M. et al. (2 more authors) (2010) Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine, 77 (3). pp. 201-205. ISSN 1297-319X

Moriceau, G., Ory, B., Gobin, B. et al. (5 more authors) (2010) Therapeutic Approach of Primary Bone Tumours by Bisphosphonates. Current Pharmaceutical Design, 16 (27). pp. 2981-2987. ISSN 1381-6128

Brounais, B., David, E., Chipoy, C. et al. (8 more authors) (2009) Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone, 44 (5). pp. 830-839. ISSN 8756-3282

Mori, K., Blanchard, F., Charrier, C. et al. (6 more authors) (2008) Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk. Cancer Science, 99 (11). pp. 2170-2176. ISSN 1347-9032

Brounais, B., Ruiz, C., Rousseau, J. et al. (4 more authors) (2008) Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption. Recent Patents on Anti-Cancer Drug Discovery, 3 (3). pp. 178-186. ISSN 1574-8928

Brounais, B., Chipoy, C., Mori, K. et al. (7 more authors) (2008) Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of midostaurin in vivo. Clinical Cancer Research, 14 (17). pp. 5400-5409. ISSN 1078-0432

Duplomb, L., Baud'huin, M., Charrier, C. et al. (4 more authors) (2008) Interleukin-6 inhibits receptor activator of nuclear factor kappa B ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: Key role of Serine(727) phosphorylation of signal transducer and activator of transcription 3. Endocrinology, 149 (7). pp. 3688-3697. ISSN 0013-7227

Ory, B., Moriceau, G.D., Trichet, V. et al. (5 more authors) (2008) Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med, 12 (3). pp. 928-941. ISSN 1582-1838

Mori, K., Berreur, M., Blanchard, F. et al. (5 more authors) (2007) Receptor activator of nuclear factor-kappa B ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncology Reports, 18 (6). pp. 1365-1371. ISSN 1021-335X

Chipoy, C., Brounais, B., Trichet, V. et al. (7 more authors) (2007) Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene, 26 (46). pp. 6653-6664. ISSN 0950-9232

Lamoureux, F., Richard, P., Wittrant, Y. et al. (8 more authors) (2007) Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: Blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Research, 67 (15). pp. 7308-7318. ISSN 0008-5472

Mori, K., Le Goff, B., Berreur, M. et al. (11 more authors) (2007) Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. The Journal of Pathology, 211 (5). pp. 555-562. ISSN 0022-3417

Ory, B., Blanchard, F., Battaglia, S. et al. (3 more authors) (2007) Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Molecular Pharmacology, 71 (1). pp. 333-343. ISSN 0026-895X

Theoleyre, S., Tat, S.K., Vusio, P. et al. (7 more authors) (2006) Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor kappa B ligand (RANKL) and RANK. Biochemical and Biophysical Research Communications, 347 (2). pp. 460-467. ISSN 0006-291X

Heymann, D. orcid.org/0000-0001-7777-0669, Ory, B., Blanchard, F. et al. (7 more authors) (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone , 37 (1). pp. 74-86. ISSN 8756-3282

Chipoy, C., Berreur, M., Couillaud, S. et al. (6 more authors) (2004) Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin m in osteosarcoma cells require PKC delta and STAT3. Journal of Bone and Mineral Research (JBMR), 19 (11). pp. 1850-1861. ISSN 0884-0431

Wittrant, Y., Theoleyre, S., Chipoy, C. et al. (4 more authors) (2004) RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1704 (2). pp. 49-57. ISSN 0304-419X